micro-community-banner
Profile Image
  • Add Media
  • Saved

2yr
Improved Lipid-Lowering Treatment and Reduction in Cardiovascular Disease Burden in Homozygous Familial Hypercholesterolemia: the SAFEHEART Follow-Up Study

Improved Lipid-Lowering Treatment and Reduction in Cardiovascular Disease Burden in Homozygous Familial Hypercholesterolemia: the SAFEHEART Follow-Up Study

Source : https://pubmed.ncbi.nlm.nih.gov/38523000/

HoFH is a severe life threating disease with a high genetic and phenotypic variability. The improvement in lipid-lowering treatment and LDL-C levels have contributed to reduce ASCVD events.

Patients with ≥1 null variant are diagnosed younger, and show a more severe phenotype with higher LDL-C levels, more aortic valve disease, and earlier onset of ASCVD.

Profile Image
  • Saved

2yr
A Preview into the American College of Cardiology Scientific Session

The American College of Cardiology will host its annual meeting (ACC.24) in Atlanta from April 6 to 8, 2024. The theme of this year’s meeting is “Transforming Cardiovascular Care for All.” Click to access some of the highlights that caught our attention.

  • Saved

2yr
Patterns and Gaps in Guideline-Directed Statin Use for Atherosclerotic Cardiovascular Disease by Race and Ethnicity

Patterns and Gaps in Guideline-Directed Statin Use for Atherosclerotic Cardiovascular Disease by Race and Ethnicity

Source : https://pubmed.ncbi.nlm.nih.gov/38525197/

In patients with incident ASCVD, we describe suboptimal and heterogenous 1-year post-ASCVD guideline-directed statin use and 1-year post-ASCVD LDL-c control across disaggregated race and ethnicity groups. Findings may improve understanding...

Disaggregation of race/ethnicity groups uncovered suboptimal and heterogenous use of statins and achievement of LDL-C control after ASCVD events.

Profile Image
  • Saved

2yr
Lipoprotein(a) Is a Prevalent yet Vastly Underrecognized Risk Factor for Cardiovascular Disease

Lipoprotein(a) Is a Prevalent yet Vastly Underrecognized Risk Factor for Cardiovascular Disease

Source : https://pubmed.ncbi.nlm.nih.gov/38525410/

Lipoprotein(a) is a Prevalent yet Vastly Underrecognized Risk Factor for Cardiovascular Disease

Lipoprotein(a) testing is essential for comprehensive CVD risk evaluation and is indicated in those with a personal or family history of premature CVD, if not all individuals.

Profile Image
  • Saved

2yr
Detailed Lipid Profiles and Lipid-Related Residual Risk After 12-Week 10 mg Rosuvastatin Treatment for Acute Myocardial Infarction

Detailed Lipid Profiles and Lipid-Related Residual Risk After 12-Week 10 mg Rosuvastatin Treatment for Acute Myocardial Infarction

Source : https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_3476-24/_article

Objective We aimed to reveal detailed on-treatment lipid profiles, lipid-related surrogate markers, and factors predicting failure to achieve the guid ...

More than one-half of the patients treated with rosuvastatin 10 mg/day with acute MI did not achieve the guideline-recommended goal of lipid management and still had lipid-related residual risk at 12 weeks.

Profile Image